Virpax rises on preclinical data for seizure treatment

Virpax Pharmaceuticals

26/04/2022 15:41

** Pain drug developer's shares  VRPX.O  rise 1.1% to $1.78 
    ** Co reports https://refini.tv/3KhoAGO preclinical study
data for its drug product candidate, VRP324, for treating
seizures associated with tuberous sclerosis complex (TSC) and
Dravet syndrome
    ** VRP324 is a nose-to-brain delivery platform for
cannabidiol (CBD)
    ** Nasal delivery of VRP324 provided high concentrations of
CBD in brain in rodent model - VRPX
    ** TSC is a genetic disorder characterized by growth of
numerous non-cancerous tumors in many parts of body while Dravet
syndrome is a rare, drug-resistant epilepsy
    ** VRPX plans to immediately engage with U.S. FDA for next
steps 

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))